Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2713–2736 of 10,533 matching trials from the local directory fallback.
Filters: Active, not recruiting Clear all
Active, not recruiting Phase 1Phase 2 Interventional

Study in Subjects With Mild-to-Moderate Alzheimer's Dementia

NCT05834296
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ALZN002 (autologous DCs pulsed with E22W mutant peptide)., Placebo
Biological · Drug
Lead sponsor
Alzamend Neuro, Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Doral, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 6, 2026, 3:35 PM EDT
Active, not recruiting Phase 1 Interventional

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

NCT05739942
View directory record Official record
Conditions
Newly Diagnosed and Recurrent Glioblastoma
Interventions
Temozolomide, [177Lu]Lu-NeoB, [68Ga]Ga-NeoB
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 10, 2026, 8:26 PM EDT
Active, not recruiting No phase listed Observational Results available

Assessing the Time Demands of Cancer

NCT05708703
View directory record Official record
Conditions
Metastatic Breast Cancer, Ovarian Cancer
Interventions
Not listed
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
2
States / cities
Birmingham, Alabama • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 15, 2026, 12:10 PM EDT
Active, not recruiting No phase listed Observational

Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI

NCT05615415
View directory record Official record
Conditions
Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection
Interventions
3T PET/MRI, MRI Tracer, PET Tracer
Device · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 10, 2026, 8:24 PM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

NCT05567796
View directory record Official record
Conditions
Obesity
Interventions
Cagrilintide, Placebo cagrilintide, Placebo semaglutide, Semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
3,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
46
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 27, 2026, 10:21 AM EDT
Active, not recruiting Phase 2 Interventional

Clinical Trial on Agitation in Alzheimer's Dementia

NCT05543681
View directory record Official record
Conditions
Aggression, Agitation,Psychomotor, Alzheimer Disease, Care Giving Burden, NPS
Interventions
IGC-AD1-Active, IGC-AD1-Placebo
Drug
Lead sponsor
IGC Pharma, LLC
Industry
Eligibility
60 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
21
States / cities
Maitland, Florida • Melbourne, Florida • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Nov 4, 2026, 2:20 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Brain Age and Sleep Architecture in Meditators

NCT05513846
View directory record Official record
Conditions
Brain Age
Interventions
DREEM EEG Device, SleepImage Ring
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 17, 2026, 10:26 PM EDT
Active, not recruiting Not applicable Interventional

Investigation to Evaluate the Safety and Effectiveness of Cochlear Implantation in Children and Adults With Unilateral Hearing Loss/Single-sided Deafness

NCT05318417
View directory record Official record
Conditions
Deafness, Unilateral, Hearing Loss, Unilateral
Interventions
The Cochlear™ Nucleus® Cochlear Implant (CI) System
Device
Lead sponsor
Cochlear
Industry
Eligibility
5 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
6
States / cities
Palo Alto, California • Englewood, Colorado • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 15, 2026, 8:56 PM EDT
Active, not recruiting Not applicable Interventional

Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis

NCT05213234
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Chronotherapy
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 16, 2026, 4:03 PM EDT
Active, not recruiting Not applicable Interventional

Evolut™ EXPAND TAVR II Pivotal Trial

NCT05149755
View directory record Official record
Conditions
Moderate Aortic Valve Stenosis
Interventions
Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT)
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
65 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2034
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Nov 3, 2026, 6:58 PM EST
Active, not recruiting Not applicable Interventional

Patient-Centered Outcomes in the Surgical Treatment of Uterovaginal Prolapse

NCT05063331
View directory record Official record
Conditions
Uterine Prolapse
Interventions
Minimally invasive supracervical hysterectomy and sacrocolpopexy (MI-SCH+SCP), Vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS)
Procedure
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
7
States / cities
Jacksonville, Florida • Chicago, Illinois • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 7, 2026, 8:25 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

NCT04989946
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cemiplimab, Degarelix, FLT PET/CT, Fianlimab, Nivolumab, pTVG-AR
Drug · Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 18, 2026, 2:01 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

NCT04980222
View directory record Official record
Conditions
Lymphoma
Interventions
Cyclophosphamide, Doxorubicin, Glofitamab, Prednisone, Rituximab, Tocilizumab, Vincristine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
10
States / cities
Duarte, California • Stanford, California • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 3, 2026, 9:54 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

NCT04835805
View directory record Official record
Conditions
Melanoma
Interventions
Belvarafenib, Cobimetinib, Nivolumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Nov 7, 2026, 1:04 PM EST
Active, not recruiting Phase 2 Interventional

An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer

NCT04733534
View directory record Official record
Conditions
Childhood Cancer, Frailty
Interventions
Dasatinib plus Quercetin, Fisetin
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 14, 2026, 3:05 PM EDT
Active, not recruiting No phase listed Observational

Evaluation of Atherosclerotic Plaques in Abdominal CT Studies

NCT04652973
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
30 Years to 90 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 15, 2026, 8:26 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Explosive Synchronization of Brain Network Activity in Chronic Pain

NCT04606095
View directory record Official record
Conditions
Fibromyalgia, Healthy Volunteers
Interventions
EEG, HD-tDCS treatments, Neuroimaging EEG/fMRI (Aim 1), Neuroimaging EEG/fMRI (Aim 3), Sham HD-tDCS treatments
Diagnostic Test · Device
Lead sponsor
University of Michigan
Other
Eligibility
19 Years to 74 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 14, 2026, 9:03 PM EDT
Active, not recruiting Phase 2 Interventional

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

NCT04560322
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Acalabrutinib, Obinutuzumab, Venetoclax
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 13, 2026, 10:24 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

NCT04197713
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Adavosertib, Olaparib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 15, 2026, 10:12 PM EDT
Active, not recruiting Phase 2 Interventional

Clinical Application of Stem Cell Educator Therapy in Alopecia Areata

NCT04011748
View directory record Official record
Conditions
Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Interventions
Stem Cell Educator therapy
Combination Product
Lead sponsor
Throne Biotechnologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 18, 2026, 5:51 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

NCT04002297
View directory record Official record
Conditions
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
Interventions
bendamustine, rituximab, zanubrutinib
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
60 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
12
States / cities
Orange, California • Chicago, Illinois • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 23, 2026, 3:48 AM EDT
Active, not recruiting Phase 3 Interventional

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

NCT03996265
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Bupropion Hydrochloride Controlled-release, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
University of Rochester NCORP Research Base
Other
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
542
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 335 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 3, 2026, 12:29 AM EDT
Active, not recruiting Phase 2 Interventional

PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product

NCT03984565
View directory record Official record
Conditions
Chronic Pain
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
Staci Gruber, Ph.D.
Other
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 13, 2026, 9:37 PM EDT
Active, not recruiting Phase 1 Interventional

AZD6738 for Patients With Progressive MDS or CMML

NCT03770429
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndrome
Interventions
AZD6738
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 13, 2026, 2:42 PM EDT